Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPRW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jasper Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jasper Therapeutics's regulatory disclosures and financial reporting.
Jasper Therapeutics, Inc. filed an 8-K reporting a material event that includes an Underwriting Agreement dated September 18, 2025 with TD Securities (USA) LLC and a set of exhibits: forms of pre-funded and common warrants, a legal opinion and consent from Paul Hastings LLP, a press release dated September 18, 2025, and an iXBRL cover page file. The filing also describes a comprehensive review and testing program for manufacturing and clinical supply lots, including robust lot testing, independent blinded testing of returned product samples, stability comparisons, and reviews of patient selection, investigational product handling, and drug delivery details. The form is signed by CFO Herb Cross on September 19, 2025. No offering terms, proceeds, or financial impacts are disclosed in the provided text.
Jasper Therapeutics is offering common stock, pre-funded warrants and common warrants to raise approximately $27.9 million in net proceeds, based on a public offering price of $2.43 per common share with an attached common warrant. The offering includes 12,345,707 common warrants (initial exercise price $2.92) and 675,000 pre-funded warrants. Shares outstanding rise from 16,219,243 to 27,889,950 assuming no warrant exercises. Net tangible book value per share was $1.45 as of June 30, 2025, estimated to increase by $0.39 to $1.84, with dilution of $0.59 per share to new investors. The filing reiterates clinical progress for briquilimab across CSU, CIndU and asthma studies showing rapid, deep responses and a favorable safety profile, but notes an ongoing investigation into two cohorts that showed an atypical absence of UAS7 reduction, with results expected in late 2025.
Jasper Therapeutics is offering common stock, pre‑funded warrants and accompanying common warrants while continuing clinical development of briquilimab, an anti–c‑Kit program in mast‑cell driven diseases. The prospectus reports preliminary Phase 1b/2a data across BEACON (CSU), SPOTLIGHT (CIndU) and an OLE: rapid onset of effect (responses as early as 1 week; complete responses by week 2), UAS7 reductions up to 29 points, dose‑dependent durability (complete responses lasting 4, 6 and 8 weeks at 120mg, 180mg and 240mg), and high cohort response rates (for example, 240mg single dose: 100% complete responses through 8 weeks; combined 240mg/360mg single‑dose cohorts: 8 of 9 (89%) complete responses). Safety is described as favorable with low‑grade, transient c‑Kit related AEs and no reported SAEs in several cohorts. An atypical absence of UAS7 reduction in two cohorts prompted an ongoing investigation including lot testing and site reviews after 10 patients dosed with one lot showed no UAS7 reductions; additional patients and alternative drug supply are being enrolled with results expected in late 2025. The company has 16,219,243 shares outstanding and lists common stock under symbol JSPR and public warrants under JSPRW. The prospectus discloses offering terms, use of proceeds for clinical development, tax and transfer limitations, and numerous risk factors including geopolitical and regulatory risks.
